Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shire Emphasizes The GI Space In Its Bid For Movetis

Executive Summary

Only five years ago, Shire's specialty pharma business consisted of one product, Adderall XR, one market, the U.S., and one patient type - children. Multiple generics companies had filed ANDAs, however, and the company was looking to broaden its base

You may also be interested in...



Shire Nabs Advanced BioHealing Just Prior To Planned IPO

Just before its planned debut on the New York Stock Exchange, wound healing device maker Advanced BioHealing Inc. instead agreed to a $750 million buyout offer May 17 from drug maker Shire PLC, which has a history of using acquisitions to jump quickly into new lines of business.

Shire Nabs Advanced BioHealing Just Prior To Planned IPO

Just before its planned debut on the New York Stock Exchange, wound healing device maker Advanced BioHealing Inc. instead agreed to a $750 million buyout offer May 17 from drug maker Shire PLC, which has a history of using acquisitions to jump quickly into new lines of business.

Shire Nabs Advanced BioHealing Before It Can Test the Public Waters

Diversifying further, the specialty outfit will spend $750 million in cash for the regenerative medicine firm and its marketed wound-healing cell therapy product.

Related Content

Topics

UsernamePublicRestriction

Register

PS052515

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel